Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Fig. 1

Flow Chart of patient collection and analysis of re-biopsies. 123 patients under EGFR TKI treatment with a PFS > 6 months and acquired resistance were rebiopsied (a). A cohort of 55 patients acquired resistance under irreversible (b) and 68 under reversible EGFR TKI therapy (c). Please note, that one afatinib-treated patient carried a primary EGFR Exon 19 duplication and was therefore excluded from the p.T790M prevalence calculation.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us